Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives
AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025
AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026
Multiple presentations at the AACR Annual Meeting highlight the promise of the pre|CISION® platform
Transformation into a pure-play therapeutics company prioritizes proprietary pre|CISION® platform and extends cash runway into Q1 2026
LONDON and PHILADELPHIA, March 31, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today provides a business update on progress for the first three months of 2025 and a review of upcoming milestones.
Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, said: 'We made a strong start to 2025, continuing to make excellent progress against all of our strategic objectives. We are very encouraged by the Phase 1 data from FAP-Dox (AVA60000) so far, which continue to show an excellent tolerability profile and increasingly durable responses in salivary gland cancers. We are now enrolling in multiple dose expansion cohorts, including triple negative breast cancer with preliminary data targeted for later in 2025.
'Our pre|CISION®-enabled exatecan program (FAP-EXd, AVA6103) also continues to progress toward a Phase 1 trial initiation early next year, underscoring our deep commitment to pioneering a novel, differentiated class of medicines to revolutionize drug delivery mechanisms. We are enthusiastic about the promise of a potent topoisomerase I inhibitor delivered in this mechanism.'
pre|CISION® Medicine Pipeline
FAP-Dox (AVA6000), a pre|CISION-enabled form of doxorubicin chemotherapy, advances to Phase 1b dose expansion. During the first quarter, Avacta completed the Phase 1a dose escalation portion of the trial, demonstrating promising early efficacy and a favorable safety profile. As of the most recent data cut-off, AVA6000 continues to show improved tolerability compared to conventional dose doxorubicin, with no observed events of severe cardiac toxicity. Encouraging progression-free survival (PFS) data has also been observed in patients with salivary gland cancers. The Company has begun enrolling patients in the Phase 1b expansion cohorts, including salivary gland cancer, triple negative breast cancer and high-grade soft tissue sarcoma and plans to report updates from these trials later in 2025. For more details see announcement from 07 March 2025 here.
AVA6103, a pre|CISION®-enabled PDC comprised of the pre|CISION peptide linked to the potent topo I inhibitor exatecan, continues preclinical development. AVA6103 is currently in investigational new drug (IND)-enabling studies with a Phase 1 trial anticipated to begin in the first quarter of 2026.
Upcoming Data Presentations at AACR. Avacta is presenting three posters at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL. The presentations will feature data from the Company's proprietary pre|CISION® platform and pipeline of next generation peptide drug conjugates (PDCs), including clinical data on AVA6000 and preclinical pharmacology highlights for AVA6103. For more details see announcement from 26 March 2025 here.
Novel data from our strategic collaboration with Tempus AI continues to be reported, including at the AACR Annual Meeting in Chicago.
Executive Leadership Team Addition
Strengthened management team. In January Avacta strengthened the management team with the appointment of Brian Hahn as Chief Financial Officer ('CFO'). Brian is a seasoned CFO with over 25 years' biopharma financial and operational experience. He spent 15 years as CFO and Senior Vice President of GlycoMimetics, Inc., where he led the company's 2014 initial public offering ('IPO') on Nasdaq.
Notice of 2024 Preliminary Results Avacta expects to report its Preliminary Results for the 12 months ended 31 December 2024 during May 2025.
For further information from Avacta, please contact:
Avacta Group plcMichael Vinegrad, Group CommunicationsDirector
www.avacta.com
Peel Hunt (Nomad and Joint Broker)James Steel / Chris Golden
www.peelhunt.com
Panmure Liberum (Joint Broker)Emma Earl / Will Goode / Mark Rogers
www.panmureliberum.com
ICR HealthcareMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert
avacta@icrhealthcare.com
Investor ContactRenee LeckTHRUST Strategic Communications
renee@thrustsc.com
Media ContactCarly ScadutoCarly Scaduto Consulting
Carly@carlyscadutoconsulting.com
About Avacta - www.avacta.com
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.
About the pre|CISION® PlatformThe pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Middle East Prepaid Card and Digital Wallet Market Growth Dynamics Databook 2025: Saudi Arabia's Unbanked Leverage Prepaid Cards for Financial Inclusion
Explore pivotal trends in the Middle East's prepaid card and digital wallet market, anticipated to reach $63.3B by 2029 with an 9.5% annual growth rate. Key drivers include digital payment adoption, financial inclusion efforts, and emerging opportunities in countries like UAE, Saudi Arabia, Qatar, and Oman. Middle Eastern Prepaid Card and Digital Wallet Market Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Middle East Prepaid Card and Digital Wallet Market Intelligence and Future Growth Dynamics Databook - Q2 2025 Update" report has been added to Middle East's prepaid card and digital wallet market is poised for remarkable growth, projected to escalate by 11.3% annually, reaching USD 44 billion by 2025. This sector experienced a strong development phase from 2020-2024, boasting a CAGR of 15.8%. The robust expansion trajectory is set to continue with a CAGR of 9.5% forecasted between 2025-2029, further propelling the market to approximately USD 63.3 billion by 2029. Key Trends and Drivers in the Middle East Prepaid Cards SectorThe prepaid card market in the Middle East is rapidly transforming, driven by digital payment advancements and financial inclusion efforts. Countries like the UAE and Qatar are integrating prepaid cards with digital wallets, reflecting a broader push towards cashless economies. Meanwhile, Saudi Arabia and Oman are leveraging prepaid solutions to address financial accessibility among unbanked populations, providing a secure and efficient alternative to traditional the next few years, the prepaid card sector is expected to expand, with government policies and financial institutions playing a crucial role in shaping market dynamics. Kuwait's retail industry and Oman's corporate sector demonstrate increased reliance on prepaid cards, indicating sector-specific growth opportunities. As financial ecosystems modernize, prepaid cards will remain a central tool for promoting financial inclusion and digital payment adoption across the Middle Initiatives Driving Digital Payment Adoption in the United Arab Emirates The UAE is experiencing a significant increase in the adoption of prepaid payment instruments, supported by government efforts to digitize the economy. This includes initiatives to promote cashless transactions and enhance financial inclusion. The government's push towards a digital economy is a primary driver of this trend. By encouraging digital payment solutions, the UAE aims to improve transaction efficiency and reduce the reliance on cash. The trend is expected to continue, with increased collaboration between the government and financial institutions to introduce innovative prepaid card solutions. This will likely lead to higher adoption rates among consumers and businesses, further embedding prepaid cards into the UAE's payment ecosystem. Rising Adoption of Prepaid Cards Among Unbanked Populations in Saudi Arabia In Saudi Arabia, prepaid cards are being used increasingly by individuals without traditional bank accounts. These cards provide a means for unbanked populations to engage in digital transactions. This trend is driven by the need for accessible financial services among unbanked individuals. Prepaid cards offer a practical solution for secure transactions without a traditional bank account. The adoption of prepaid cards among unbanked populations is expected to grow, contributing to greater financial inclusion in Saudi Arabia. Financial institutions may develop more tailored prepaid card products to meet the specific needs of this demographic. Integration of Prepaid Cards with Digital Wallets in Qatar Qatar is witnessing the integration of prepaid cards with digital wallet platforms, allowing users to manage funds and make payments through their smartphones. The increasing penetration of smartphones and the demand for convenient payment solutions drive this trend. Consumers prefer the ease of managing finances digitally, which prepaid cards linked to mobile wallets facilitate. This integration is expected to deepen, with more financial institutions partnering with technology providers to offer seamless prepaid card and digital wallet solutions. This will likely enhance the user experience and promote cashless transactions in Qatar. Growth of Prepaid Gift Cards in the Retail Sector in Kuwait Kuwait's retail sector is experiencing an increase in the issuance and use of prepaid gift cards, particularly during festive seasons and special occasions. Retailers are adopting prepaid gift cards to boost sales and attract customers. Consumers appreciate gift cards' flexibility, making them a popular choice for gifting. The trend is expected to intensify, with more retailers launching customized prepaid gift card programs. This will likely increase consumer engagement and loyalty in Kuwait's retail market. Corporate Adoption of Prepaid Payroll Cards in Oman In Oman, companies are increasingly utilizing prepaid payroll cards to disburse salaries to employees, especially those without bank accounts. The need for efficient and secure salary disbursement methods drives this trend. Prepaid payroll cards offer a practical solution for employers to pay unbanked employees, ensuring timely and transparent transactions. Prepaid payroll cards are expected to expand, with more companies adopting this method to streamline payroll processes. This will contribute to financial inclusion and improve the financial well-being of employees in Oman. Competitive Landscape of the Middle East Prepaid Card MarketThe Middle East's prepaid card market is evolving rapidly, fueled by digital transformation, financial inclusion initiatives, and the growing demand for cashless payment solutions. Established financial institutions and fintech startups actively expand their offerings, leveraging strategic partnerships to enhance market regulatory frameworks continue to adapt to the changing financial landscape, companies must balance compliance with innovation to remain competitive. The next few years will be critical in determining which players successfully capitalize on emerging opportunities, shaping the region's future of prepaid payment Market Dynamics The rising adoption of prepaid cards in e-commerce, transportation, and corporate payroll solutions supports the market's growth. With many unbanked populations in the region, prepaid cards have become an essential financial tool, offering secure and accessible payment alternatives. Additionally, fintech companies are driving innovation, introducing digital wallets linked to prepaid cards, further expanding the market's reach. Key Players and Market Share The prepaid card market in the Middle East is highly competitive, with a mix of global financial institutions and emerging fintech players. Leading companies such as Visa, Mastercard, American Express, and Carrefour SA dominate the market, offering a diverse range of prepaid card solutions for personal, corporate, and travel-related transactions. These companies have established strong distribution networks, leveraging partnerships with banks and retail chains. In addition to traditional financial institutions, fintech firms are entering the market with innovative prepaid card solutions tailored to regional needs. Companies like YouGotaGift, a digital gift card provider, have expanded their presence through partnerships with major retailers such as Carrefour. Meanwhile, regional fintech startups in Saudi Arabia and the UAE are launching prepaid card solutions integrated with mobile wallets, catering to the growing demand for digital financial services. Recent Launches and Partnerships Strategic collaborations and partnerships are crucial in the evolution of the prepaid card market in the Middle East. One notable partnership is YouGotaGift's collaboration with Carrefour, which has expanded the availability of digital prepaid gift cards, addressing the rising demand for digital gifting solutions. Additionally, banks and fintech firms are forming alliances to integrate prepaid card services with digital payment platforms, enhancing consumer convenience. While direct mergers and acquisitions in the prepaid card segment remain limited, broader financial sector consolidations impact the market. Large financial institutions are acquiring smaller fintech firms to strengthen their prepaid card portfolios and expand their customer base. This trend is expected to intensify as traditional banks seek to enhance their digital offerings by leveraging the technological capabilities of fintech startups. Anticipated Market Evolution (Next 2-4 Years) The prepaid card market in the Middle East is expected to become increasingly competitive over the next few years. The entry of new fintech firms and the expansion of services by existing players will drive further innovation. Integrating prepaid cards with digital wallets and mobile payment solutions will likely become a key differentiator, with companies focusing on enhancing customer convenience and security. Regulatory developments will also play a crucial role in shaping the market. As governments implement stricter financial regulations, prepaid card providers must navigate compliance challenges while maintaining product innovation. Additionally, the push for financial inclusion will create opportunities for companies to introduce prepaid solutions tailored to unbanked and underbanked populations, further driving market growth. Regulatory Changes Regulatory bodies in the Middle East have introduced new measures to enhance consumer protection and improve financial transparency in the prepaid card industry. Governments across the region are focusing on strengthening anti-money laundering (AML) and know-your-customer (KYC) compliance frameworks to ensure secure prepaid card transactions. These regulations aim to reduce fraud risks and increase trust in digital payment solutions. Central banks in countries like Saudi Arabia and the UAE have also introduced guidelines to facilitate the seamless integration of prepaid cards with mobile payment systems. These changes enhance the financial ecosystem, providing consumers with more secure and convenient digital transaction options. As regulatory frameworks continue to evolve, prepaid card issuers must ensure compliance while maintaining a seamless user experience. This report provides a detailed data-centric analysis of the prepaid card and digital wallet industry in Middle East, covering market opportunities and analysis across a range of prepaid card and digital wallet domains. With over 80+ KPIs at the country level, this report provides a comprehensive understanding of prepaid card and digital wallet market dynamics, market size and forecast, and market share Attributes: Report Attribute Details No. of Pages 636 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $44 Billion Forecasted Market Value (USD) by 2029 $63.3 Billion Compound Annual Growth Rate 9.5% Regions Covered Middle East Report ScopeThis report offers an in-depth, data-driven examination of prepaid payment instruments, focusing on expenditures via prepaid cards and digital wallets within both retail and corporate consumer sectors. It also presents an overview of global consumer behavior and retail spending patterns. The report includes a detailed breakdown of key market segments for each country. Prepaid Payment Instrument Market Size and Forecast Digital Wallet Market Size and Forecast Digital Wallet Market Size and Forecast by Key Segments Digital Wallet Retail Spend Dynamics Prepaid Card Industry Market Attractiveness Open Loop Prepaid Card Future Growth Dynamics Closed Loop Prepaid Card Future Growth Dynamics Prepaid Card Consumer Usage Trends Prepaid Card Retail Spend Dynamics General Purpose Prepaid Card Market Size and Forecast Gift Card Market Size and Forecast Gift Card Market Size and Forecast by Consumer Segments Gift Card Market Share Analysis by Retail Categories Entertainment and Gaming Prepaid Card Market Size and Forecast Teen and Campus Prepaid Card Market Size and Forecast Business and Administrative Expense Prepaid Card Market Size and Forecast Payroll Prepaid Card Market Size and Forecast Meal Prepaid Card Market Size and Forecast Travel Forex Prepaid Card Market Size and Forecast Transit and Tolls Prepaid Card Market Size and Forecast Social Security and Other Government Benefit Programs Prepaid Card Market Size and Forecast Fuel Prepaid Cards Market Size and Forecast Utilities, and Other Prepaid Cards Market Size and Forecast Virtual Prepaid Card Industry Market Attractiveness Virtual Prepaid Card Market Size by Key Categories For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Middle Eastern Prepaid Card and Digital Wallet Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
Autoimmune Collaboration and Licensing Deals Report 2025: Comprehensive Analysis of 943 Autoimmune Licensing Deals (2016-2025) Across 30+ Diseases
The 2025 report on Autoimmune Collaboration & Licensing Deals analyzes 943 agreements from 2016-2025, covering over 30 diseases including MS, RA, lupus, and Crohn's. Access deal terms, financials, and SEC contracts for top biopharma partnerships. A must-have for benchmarking, due diligence, and strategic planning in autoimmune R&D and commercialization. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Autoimmune Collaboration and Licensing Deals 2016-2025" report has been added to Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the worlds leading biopharma revised and updated, the report provides details of 943 autoimmune deals from 2016 to report includes coverage of the following autoimmune diseases:Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their initial chapters provide a valuable orientation to autoimmune dealmaking, beginning with an introduction in Chapter 1. Chapter 2 delves into trends within autoimmune dealmaking, offering a comprehensive analysis. The subsequent chapters provide detailed insights, covering the financial aspects of deals (Chapter 3), reviewing top active companies (Chapter 4), examining notable signed deals (Chapter 5), and presenting a directory organized by therapeutic target (Chapter 6).The report also includes numerous table and figures that illustrate the trends and activities in autoimmune deal making since addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse autoimmune collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Report ScopeAutoimmune Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of autoimmune trends and structure of deals entered into by leading biopharma companies Collaboration and Licensing Deals includes: Trends in autoimmune dealmaking in the biopharma industry Overview of collaboration and licensing deal structure Directory of autoimmune deal records covering pharmaceutical and biotechnology The leading autoimmune deals by value Most active autoimmune licensing dealmakers In Autoimmune Collaboration and Licensing Deals, the available deals are listed by: Company A-Z Headline value Therapeutic area Technology type Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Chapter 1 - IntroductionChapter 2 - Trends in autoimmune dealmaking2.1. Introduction2.2. Autoimmune deals over the years2.3. Autoimmune deals by deal type2.4. Autoimmune deals by industry sector2.5. Autoimmune deals by stage of development2.6. Autoimmune deals by technology typeChapter 3 - Financial deal terms for autoimmune deals3.1. Introduction3.2. Disclosed financials terms for autoimmune deals3.3. Autoimmune deal headline values3.4. Autoimmune deal upfront payments3.5. Autoimmune deal milestone payments3.6. Autoimmune deal royalty ratesChapter 4 - Leading autoimmune dealmakers and deals4.1. Introduction4.2. Most active in autoimmune dealmaking4.3. List of most active dealmakers in autoimmune4.4. Top autoimmune deals by valueChapter 5 - Autoimmune deal contract document directory5.1. Introduction5.2. Autoimmune partnering deals where contract document availableChapter 6 - Autoimmune dealmaking by therapeutic target6.1. Introduction6.2. Deals by autoimmune therapeutic targetDeal Directory Deal Directory - Autoimmune deals by company A-Z 2016 to 2025 Deal Directory - Autoimmune deals by technology type 2016 to 2025 A Selection of Companies Featured Include: AB Biosciences Abbott Laboratories Abbvie Acucela Aculys Pharma AdAlta Adhera Therapeutics Adimune Adiso Therapeutics Aditum Bio Aduro BioTech Adynxx Agility Life Sciences AimedBio Akaal Pharma Akebia Therapeutics Akouos Akston Biosciences Alex Therapeutics Alfasigma Alimentiv Alimera Sciences Alkermes Almirall AltaVoice Alvotech Amarna Therapeutics Ambiopharm Ambry Genetics Amegabiotech Amgen Amytrx Therapeutics AnaptysBio AnGes MG Anokion Anthem Bluecross AntibioTx Antidote Aptar Pharma Arbor Biotechnologies Arch Biopartners Arctic Vision Arcutis Biotherapeutics Arena Pharmaceuticals Aristea Therapeutics Ark Biosciences Aslan Pharma Aspect Biosystems Astellas Pharma Asthma UK AstraZeneca Astria Therapeutics Autolus Avacta Avalere Health Avicanna Axela Axoltis Pharma Axsome Therapeutics Azenta Life Sciences Azitra Bachem Back-A-Line Basilea Pharmaceutica Bausch & Lomb Bayer BCD Bioscience BenevolentAI Bennu Pharmaceuticals BGI Bigfoot Biomedical BinnoPharm Bio-Gate Bio-Path Bio-Rad Laboratories Bio-Techne BioClinica Biocon Biofourmis Biogen Bioqube Ventures Boehringer Ingelheim Boragen Boston Pharmaceuticals Brain Canada Brainomix Brickell Biotech Bristol-Myers Squibb C4X Discovery Cabaletta Bio Caladrius Biosciences Calliditas Therapeutics Candid Therapeutics Cantargia Cara Therapeutics CASI Pharmaceuticals Celltrion Celmatix Celsius Therapeutics Centessa Pharmaceuticals Centurion Century Therapeutics Charles River Laboratories CheckPoint Immunology Chugai Pharmaceutical Cipla Circassia Clearside Biomedical Clene Nanomedicine Cleveland Clinic ClinConnect Coeptis Therapeutics Collplant Conduit Pharmaceuticals Corrona Cosmofix Coya Therapeutics Cryostem CrystalGenomics CSL Behring Cugene Curant Health Cynata Therapeutics Cyrus Biotechnology Cytocom Daewoong Pharmaceutical Daiichi Sankyo Danuo Science Group Debiopharm Diurnal Diversigen DNAnexus Dr. Falk Pharma Dr. Reddy's Laboratories Dragonfly Therapeutics DreaMed Diabetes DyDo Pharma Editas Medicine EffRx Pharmaceuticals Eisai Eli Lilly ElsaLys Biotech Encore Dermatology Endo International Engitix Enosi Therapeutics Ensho Therapeutics Entera Health Enteris Biopharma Enzene Biosciences EOFlow Epicore Biosystems EpimAb Biotherapeutics epitoMAP Epivax Equillium Eterna Therapeutics Ethypharm EVA Pharma Evidation Health Evofem Biosciences Evolve BioSystems Evommune EVOQ Therapeutics Evotec Ewopharma Exagen Diagnostics Excelra Exscientia Fibrogen Fluidigm Fosun Pharmaceutical Frequency Therapeutics FSD Pharma Fujifilm Fuji Pharma FutureGen Biopharm G42 Healthcare Galderma GC Biopharma GenEdit Genentech Genetic Analysis Genmab Genomics Genprex GenScript ProBio Genten Therapeutics GentiBio Genzyme Georgiamune Giiant Pharma Gilead Sciences Glenmark Pharmaceuticals Graviton Bioscience GRI Bio GSK Gusto Global Gynica Halozyme Therapeutics Hansa Biopharma Haplogen Hesperos HIBio Hoffmann La Roche Honeywell Horizon Therapeutics Humanigen IMIDomics Immetas Therapeutics ImmPACT Bio Immugenyx ImmunoAdoptive Cell Therapy ImmunogenX Inception Sciences Incyte InDex Pharmaceuticals Inexia Innate Pharma Inserm Transfert InSilicoTrials Insmed Inc Integral Molecular Intract Pharma Intrexon Inventiva Ionis Pharmaceuticals IQVIA ISD Immunotech Iterative Scopes iTolerance Izana Bioscience Jackson Laboratory Janssen Biotech Jazz Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson Jolt Health JSR Jubilant Radiopharma Jubilant Therapeutics Jupiter Wellness JW Pharmaceutical Kadimastem Kadmon Pharmaceuticals Kaleido Biosciences Kamada KBI BioPharma Kezar Life Sciences Kindeva Drug Delivery Kiniksa Pharmaceuticals Kissei Pharmaceutical Kite Pharma Klue Komodo Health Koneksa Health Koye Pharmaceuticals Kubota Vision Landos Biopharma Lassen Therapeutics LEO Pharma Lexicon Pharmaceuticals LianBio Lipidor Lonza Lyfebulb LyGenesis Mabwell Bioscience mAbXience Mapi Pharma Marengo Therapeutics Maruho Max Biopharma Maxcyte Medac Medgenics Medimetriks Medison Pharma MedRhythms Medsenic Meiji Seika Merck and Co Metaba Microdrop Mimetas MiNA Therapeutics MiTest Health Moderna MorphoSys Mundipharma Mylan Laboratories Myovant Sciences Myriad Genetics Navidea Biopharmaceuticals Nektar Therapeutics Neogap Therapeutics Neoteryx Neovacs Neovii Pharmaceuticals Neurodon NeuroGenesis Nexel Nexilico Nippon Shinyaku Nitto Denko Nkarta Therapeutics NLS Pharmaceutics Nona Biosciences Nordic Pharma Group Novartis Novo Nordisk Nuance Pharma Nuevolution Numab Numares NuMedii Nutra Pharma Nxera Pharma Ocumension Therapeutics OliX Pharmaceuticals OMNY Health Orion Ossium Health Otsuka Paladin Labs Palisade Bio Palleon Pharmaceuticals Panaxia Pancryos Pandion Therapeutics Paragon Bioservices Parexel Biotech Parvus Therapeutics Patara Pharma PathoQuest Pearsanta Pediatrix Therapeutics Pelle Ventures Pfizer Pheno Therapeutics Philips PicnicHealth PlantEXT Pluristyx Pragma Bio Precision BioSciences PredictImmune Priovant Therapeutics Progenity Promius Pharma Propeller Health Protagen Protxx Purdue Pharma Quadri Pharmaceuticals Recipharm RedHill Biopharma Redx Pharma Regen BioPharma Regentys Regranion Relife Remedium Bio Renovion ReproCell RespirAI Medical Revive Therapeutics Revon Systems ReWalk Robotics Rheos Medicines Rigel Pharmaceuticals Roche Roivant Sciences RS BioTherapeutics Sandoz Sanguine Sanofi Sano Genetics Savana Scailyte Schrodinger Scienion Scipher Medicine Second Genome Selecta Biosciences Selexis Semma Therapeutics Sengenics Seres Therapeutics Sernova Serosep Shaperon Shire Laboratories Siemens Healthineers Sigilon Therapeutics Signum Biosciences Sirion Biotech Sitryx Skyhawk Therapeutics SomaLogic Sonde Health Sonoma BioTherapeutics Sorrento Therapeutics Statera Biopharma Surrozen SynAct Pharma Synaptogenix Syndax Pharmaceuticals Syneron Bio Synlogic Synthekine Synthonics Taiho Takara Bio Takeda Pharmaceutical Teva Pharmaceutical Industries TG Therapeutics Tharimmune Theradiag Theramex TiGenix Tiziana Life Sciences TONIX Pharmaceuticals Trethera True Diagnostics True North Therapeutics Truveta TxCell UCB UGA Biopharma Upsher-Smith Vaccinex Valo Health Variant Bio Vcell Healthcare Vectura Veracyte Verily Verona Pharma Versant Ventures Vicore Pharma Vital Therapies Vium Vivtex Voronoi Wanchunbulin WellDyne WuXi Biologics Xbrane Biopharma Xencor Xylyx Bio Zedira Zymeworks ZyVersa Therapeutics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
XPENG Announces New G6 and G9 Ultra Smart SUVs for Europe
Redefining Performance, Design, and Intelligent Technology for the Next Generation of Electric Vehicles. Powered by Industry-Leading Powertrain Technology: 5C Supercharging Battery and 800V High-voltage SiC Platform across all trims. Charging Speed 12 minutes 10-80% SOC placing it at the forefront of the EV revolution. Smart Comfort Meets All-New Interior and Cockpit Upgrades. Expressive New Colors Inside and Out, adding individuality and Appeal. AMSTERDAM, June 12, 2025 (GLOBE NEWSWIRE) -- XPENG, a leading global smart electric vehicle (EV) manufacturer driven by innovation and advanced AI technology, is proud to unveil the new versions of its Ultra Smart Coupe SUV XPENG G6 and Ultra Smart Premium SUV XPENG G9 for the European market. Both models have been upgraded inside and out and feature XPENG's next-gen full-domain 800V high-voltage SiC platform alongside a 5C supercharging battery. This enables ultra-fast charging up to 525 kW for the new XPENG G9 and 451kW for the new XPENG G6, leading in their class. The new XPENG G6, featuring a complete overhaul and a new color Stellar Purple, will be on static display at Le Mans Village in France starting today. European customers can now register their interest for both models via XPENG's official websites in the Netherlands, Belux, Norway, Denmark, Sweden, Germany, and France. Order will open from XPENG G6 and G9 The Heart of Innovation: The Supercharging Battery Upgraded from 3C to 5C At the core of the new XPENG G6 and G9 is an industry-first upgrade to 5C lithium iron phosphate (LFP) batteries for all trims. This next-gen battery technology offers a safer, more eco-friendly solution by eliminateing the need for resource-intensive and costly minerals such as cobalt and nickel, making the version more sustainable without compromising performance. Both models are equipped with XPENG's industry-leading powertrain technology, including the 5C Supercharging Battery and a full-domain 800V high-voltage SiC platform, available across all trims. The result is exceptional charging speed with a 10-80% State of Charge (SOC) achieved in just 12 minutes, setting new benchmarks. XPENG continues to lead in intelligent driving technology. The new XPENG G6 and G9 features a full upgraded intelligent driving suite, including a MicroFiber capacitance steering wheel, advanced driving chip and single-pixel Lofic architecture for accurate, clearer and longer-range perception for enhanced safety and control. Complementing the driving experience is an upgraded cockpit powered by a high-performance cockpit chip and support for Apple CarPlay & Android Auto as standard, ensuring a smarter, smoother and more joyful 800V High-voltage SiC Platform Revolutionary Design Enhancements The new XPENG G6 is as much about style as it is about substance. The exterior is defined by the all-new 1942 mm full-width Starlight Wing LED light bar, integrated turn signals, and a redesigned rear diffuser for a cleaner finish. The new XPENG G6 Stellar Purple features a low-saturation neutral purple tone with metallic flakes infused into the paint, creating a gradient effect shifting from deep purple to light purple under changing light. Its matte metallic finish glimmers subtly like starlight in the sun, blending a sense of mystery with technology. When paired with the new XPENG G6's streamlined coupe-SUV body, it exudes both elegance and sporty dynamism, setting a benchmark for color aesthetics in the smart mobility XPENG G6 The new XPENG G9 Black Edition delivers an equality captivating presence, dressed in a deep midnight black paint paired with blackened wheels, logos, and fender decorations. The fiery orange brake calipers create a striking visual contrast, adding a mysterious yet sharp XPENG G9 Inside, the new XPENG G6 boasts a completely re-imagined interior that focuses on premium materials, immersive technology, and comfort. The new Super Star-Ring Interior Design has transformed 60% of the cabin, introducing a sleek new dashboard, ambient lighting, and a new capacitive steering wheel. Premium materials and immersive design define the cabin with refined color themes - Dark Gray and Light Gray - enhancing the ultra-modern ambiance. Both the new XPENG G6 and G9 have received significant upgrades in comfort and smart functionality. New XPENG G6: Front seats feature a massage function with lumbar support, delivering refined comfort for both driver and passenger. New XPENG G9: A luxury comfort upgrade featuring an ultra-large three-layer heat-insulating panoramic sunroof, luxurious comfort seats with 10-point XPENG G6 InteriorNew XPENG G9 Interior About XPENG Founded in 2014, XPENG is a leading Chinese AI mobility company that designs, develops, manufactures, and markets intelligent electric vehicles, catering to a growing base of tech-savvy consumers. With the rapid advancement of AI, XPENG aspires to become a global leader in AI mobility, with a mission to lead the intelligent electric vehicle revolution through cutting-edge technology, shaping the future of mobility. To enhance the customer experience, XPENG in-house develops its advanced driver assistance technology (ADAS) and intelligent in-car operating system, along with core vehicle systems such as powertrain and electrical/electronic architecture (EEA). Headquartered in Guangzhou, China, XPENG also operates key offices in Beijing, Shanghai, Silicon Valley, and Amsterdam. Its intelligent electric vehicles are mainly produced at its plants in Zhaoqing and Guangzhou, Guangdong Province. XPENG is listed on the New York Stock Exchange (NYSE: XPEV) and the Hong Kong Stock Exchange (HKEX: 9868). For more information, visit Contacts: For Media Enquiries: XPENG PR Department Email: pr@ Photos accompanying this announcement are available at in to access your portfolio
